Pfizer trims expectations for 2023 with sales of COVID-19 vaccine, treatment, weaker than thought

Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year.


Please follow and like us: